How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
Dr. Alex Adjei offers options to make cancer care more cost-effective, such as selecting only patients who will benefit from treatment and continuing to offer treatments that will allow patients to remain in the workforce.